Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study-Reference-Cited by-同舟云学术

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

Published:2021-10-21 Issue:3 Volume:196 Page:639-648
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Larocca Alessandra¹^ORCID,Leleu Xavier²,Touzeau Cyrille³⁴⁵^ORCID,Bladé Joan⁶,Paner Agne⁷,Mateos María‐Victoria⁸^ORCID,Cavo Michele⁹,Maisel Christopher¹⁰,Alegre Adrían¹¹,Oriol Albert¹²,Raptis Anastasios¹³,Rodriguez‐Otero Paula¹⁴^ORCID,Mazumder Amitabha¹⁵,Laubach Jacob¹⁶^ORCID,Nadeem Omar¹⁶,Sandberg Anna¹⁷,Orre Marie¹⁷,Torrång Anna¹⁸,Bakker Nicolaas A.¹⁷,Richardson Paul G.¹⁶^ORCID

Affiliation:

1. Myeloma Unit Division of Hematology University of Torino Azienda Ospedaliero – Universitaria Città della Salute e della Scienza Turin Italy

2. CHU de Poitiers PoitiersFrance

3. Centre de Recherche en Cancérologie et Immunologie Nantes‐Angers (CRCINA) Institut National de la Santé et de la Recherche Médicale (INSERM) Centre National de la Recherche Scientifique (CNRS) Université d’Angers Université de Nantes NantesFrance

4. Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision‐making (ILIAD) NantesFrance

5. Service d’Hématologie Clinique Centre Hospitalier Universitaire Place Alexis Ricordeau Nantes France

6. Hematology Department IDIBAPS, Hospital Clinic Barcelona Spain

7. Rush University Medical Center Chicago IL USA

8. Hospital Clínico Universitario de Salamanca/IBSAL/CIC Salamanca Spain

9. IRCCS Azienda Ospedaliero‐Universitaria di Bologna Seràgnoli Institute of Hematology Bologna University School of Medicine Bologna Italy

10. Baylor Scott & White Charles A. Sammons Cancer Center Dallas TX USA

11. Hospital Universitario La Princesa and Hospital Universitario Quironsalud MadridSpain

12. Institut Català d’Oncologia and Josep Carreras Research Institute Hospital Germans Trias i Pujol Badalona Spain

13. Division of Hematology‐Oncology Department of Medicine University of Pittsburgh School of Medicine Pittsburgh PA USA

14. Clínica Universidad de Navarra Pamplona Spain

15. The Oncology Institute of Hope and Innovation Glendale CAUSA

16. Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA

17. Oncopeptides AB StockholmSweden

18. SDS Life Science Danderyd Sweden

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17887

Reference36 articles.

1. Multiple Myeloma

2. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study

3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

4. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone

5. How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

3. Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM‐3;British Journal of Haematology;2024-02-29

4. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study;Frontiers in Oncology;2023-12-07

5. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study;Clinical Lymphoma Myeloma and Leukemia;2023-11